Biotech Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
A.P. Pharma, Inc.
Clinical endpoints achieved in phase II trial of anti-nausea drug
November 4th, 2005
A.P. Pharma, Inc., (APPA) reported results from its APF530 phase II clinical trial. All clinical endpoints were achieved and results support advancement of APF530 into pivotal clinical trials. The primary endpoints included an evaluation of safety, pharmacokinetics and tolerability. In addition, efficacy endpoints were evaluated relating to emetic events and the use of rescue medication. The overall results of this phase II study compare very favorably with published results of other anti-emetic products, and support APF530 advancing into pivotal clinical trials, planned to be initiated in the fourth quarter of 2005, subject to ratification by the...
Source: Biotech Law Weekly (2005-11-04)
|
